L-061-2022
Agreement ID
L-061-2022
Lead IC
NCI
Exclusivity
Exclusive
External Party
Sana Biotechnology, Inc.
Fiscal Year
2022
Territory
Worldwide
Execution Date
Effective Date
Export Date
Technologies
TAB-4346 Human and Improved Murine Monoclonal Antibodies Against CD22
TAB-4223 Chimeric Antigen Receptors to CD22 for Treating Hematological Cancers
TAB-4268 Bivalent, Dual Specific Anti-CD22 Anti-CD19 Chimeric Antigen Receptors (CARs)
TAB-4017 Dual Specific Anti-CD22 Anti-CD19 Bicistronic Chimeric Antigen Receptors (CARs)
TAB-4223 Chimeric Antigen Receptors to CD22 for Treating Hematological Cancers
TAB-4268 Bivalent, Dual Specific Anti-CD22 Anti-CD19 Chimeric Antigen Receptors (CARs)
TAB-4017 Dual Specific Anti-CD22 Anti-CD19 Bicistronic Chimeric Antigen Receptors (CARs)